Abstract In normal wound healing, resident fibroblasts transition to myofibroblasts, which function to contract and close wounds. In pathologic conditions where wounds fail to heal (such as diabetes), fibroblasts do not increase myofibroblast gene expression; this mechanism is poorly understood. Using human wound scSeq and murine transgenic models, we examined the epigenetic mechanisms that may regulate this transition in the setting of injury. First, we identify that the cytokine TGFb increases myofibroblast genes in vitro. We performed an epigenetic superarray on TGFb-stimulated dermal fibroblasts, where JMJD3, an H3K27 demethylase, was significantly upregulated and was also confirmed by qPCR. ScSeq of human wounds identified JMJD3 as strongly upregulated in myofibroblasts. ChIP identified decreased H3K27me3, the activating mark of JMJD3 at myofibroblast genes further confirming its role in regulating myofibroblast genes. SiRNA knockdown of JMJD3 led to reduced myofibroblast gene expression. These findings were confirmed in a novel, tamoxifen induced, fibroblast specific knockout of JMJD3 unique to our lab. An unbaised superarray focused on remodelling and cell adhesion pathways identified that these mice have deficient levels of many structural and remodelling genes. Murine wounds were found to upregulate JMJD3 compared to distant skin, which was less pronounced in diabetic wounds. This work identifies JMJD3 as a TGFb-mediated regulator of fibroblast to myofibroblast transition.
Read full abstract